Epilepsy is one of the most common neurological disorders, affecting around 50 million people worldwide. Advances in epilepsy imaging and treatment (e.g. ablative and neurostimulation procedures, and new antiepileptic drugs) have decreased seizure frequency and severity. Yet unmet needs remain with approximately 30% of people with epilepsy refractory to pharmacotherapies. Novel therapeutic targets include AMPA receptors, potassium channels and synaptic vesicle protein 2A. Ongoing developments and improved understanding of the genetics of epilepsy subtypes may provide patient-specific solutions.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.
Our supporting partners do not constitute an endorsement of the content on this page.
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
New data shaping diagnosis, treatment strategies and long-term management in epilepsy The American Epilepsy Society Annual Meeting 2025 brought together leading experts to showcase the latest developments in epilepsy research and clinical care. The meeting highlighted significant progress in Dravet Syndrome, ...
The International League Against Epilepsy (ILAE) is a leading global organisation devoted to epilepsy research, education, advocacy and care. Founded in 1909, it now comprises more than 120 national chapters worldwide and serves as a premier resource for clinicians, scientists and public-health ...
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Expert faculty discuss the management of patients with Lennox–Gastaut syndrome in Japan and the Gulf
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Dravet Syndrome UK’s team participated in the 36th International Epilepsy Congress (IEC 2025) in Lisbon, joining clinicians, researchers, pharmaceutical developers and patient advocates focused on Dravet Syndrome and related epileptic encephalopathies. Several key themes emerged that signal progress towards disease-modification, more patient‑centred trials, and enhanced outcome measures beyond simple seizure counts.
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1Â Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
Dravet Syndrome UK has launched the Little Moments Matter Awards, a new programme that celebrates the healthcare, social care and education professionals whose dedication provides vital support to families living with Dravet syndrome. Nominations are open until 31 August 2025, and the winners will be announced at DSUK’s Professionals Conference in November.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.